다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of hospice and palliative care, v.26 no.1, 2023년, pp.18 - 21
Se-Il Go (Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine) , Jung Hoon Kim (Department of Internal Medicine, Gyeongsang National University College of Medicine) , Jung Hun Kang (Department of Internal Medicine, Gyeongsang National University College of Medicine)
AI-Helper
The combination of oxycodone and naloxone is useful for cancer pain management. Naloxone, as a pure opioid antagonist, cannot be used simultaneously with opioids. However, owing to its low bioavailability, it can be used in an oral composite formulation. We present the case of a 55-year-old man with...
1 Reid CM Martin RM Sterne JA Davies AN Hanks GW 2006 Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials Arch Intern Med 166 837 43 10.1001/archinte.166.8.837 16636208
2 Ahmedzai SH Nauck F Bar-Sela G Bosse B Leyendecker P Hopp M 2012 A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain Palliat Med 26 50 60 10.1177/0269216311418869 21937568
3 Meissner W Schmidt U Hartmann M Kath R Reinhart K 2000 Oral naloxone reverses opioid-associated constipation Pain 84 105 9 10.1016/S0304-3959(99)00185-2 10601678
4 Smith K Hopp M Mundin G Bond S Bailey P Woodward J 2012 Low absolute bioavailability of oral naloxone in healthy subjects Int J Clin Pharmacol Ther 50 360 7 10.5414/CP201646 22541841
5 Rzasa Lynn R Galinkin JL 2018 Naloxone dosage for opioid reversal: current evidence and clinical implications Ther Adv Drug Saf 9 63 88 10.1177/2042098617744161 29318006
6 Wong A Macleod D Robinson J Koutsogiannis Z Graudins A Greene SL 2015 Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally Clin Toxicol (Phila) 53 815 8 10.3109/15563650.2015.1060486 26109423
8 Kang JH Lee GW Shin SH Bruera E 2013 Opioid withdrawal syndrome after treatment with low-dose extended-release oxycodone and naloxone in a gastric cancer patient with portal vein thrombosis J Pain Symptom Manage 46 e15 7 10.1016/j.jpainsymman.2013.02.009 23680581
9 Vanden Hoek TL Morrison LJ Shuster M Donnino M Sinz E Lavonas EJ 2010 Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Circulation 122 S829 61 10.1161/CIRCULATIONAHA.110.971069 20956228
10 Bellingan M 2017 What drug?: Naloxone Australian Pharmacist 36 54 7
11 Pergolizzi JV Jr Raffa RB Rosenblatt MH 2020 Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management J Clin Pharm Ther 45 892 903 10.1111/jcpt.13114 31986228
12 Yu E Miotto K Akerele E Montgomery A Elkashef A Walsh R 2008 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal Drug Alcohol Depend 97 158 68 10.1016/j.drugalcdep.2008.04.002 18508207
13 Gowing L Farrell MF Ali R White JM 2014 Alpha2-adrenergic agonists for the management of opioid withdrawal Cochrane Database Syst Rev CD002024 10.1002/14651858.CD002024.pub4 24683051
14 Jung S Rosini JM 2017 Dexmedetomidine for treatment of refractory heroin withdrawal J Emerg Nurs 43 182 4 10.1016/j.jen.2017.01.004 28372774
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.